Cytotoxic Lesion in the Splenium of Corpus Callosum Secondary to Subacute Methotrexate Neurotoxicity.

Avicenna J Med

Department of Neurology, University of Missouri, Columbia, Missouri, United States.

Published: July 2021

Methotrexate neurotoxicity can present with a wide spectrum of neurologic symptoms and brain magnetic resonance imaging (MRI) typically demonstrates cerebral edema, demyelination, multifocal white matter necrosis, and atrophy relatively selective for the deep cerebral white matter. Here, we report a case of subacute methotrexate neurotoxicity in a 40-year-old man with B cell acute lymphoblastic leukemia. Brain MRI showed cytotoxic lesion in the splenium of corpus callosum and left middle cerebellar peduncle. Patient significantly improved 24 hours after receiving oral dextromethorphan. Methotrexate neurotoxicity should be suspected in any symptomatic patient receiving high dose of methotrexate or intrathecal methotrexate therapy. Dextromethorphan should be considered in these patients as it can modulate the excitatory responses to homocysteine and its metabolite which are usually elevated in such patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500069PMC
http://dx.doi.org/10.1055/s-0041-1732486DOI Listing

Publication Analysis

Top Keywords

methotrexate neurotoxicity
16
cytotoxic lesion
8
lesion splenium
8
splenium corpus
8
corpus callosum
8
subacute methotrexate
8
white matter
8
methotrexate
6
callosum secondary
4
secondary subacute
4

Similar Publications

<b>Background and Objective:</b> Methotrexate is an anti-metabolic medication used to treat cancer. It causes oxidative stress in nerve tissue and has neurotoxic effects. A strong antioxidant and effective free radical scavenger is vitamin C.

View Article and Find Full Text PDF

Background: Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate clearance and transport in toxicity susceptibility in children with ALL is not well established. Therefore, we evaluated the association between suspected methotrexate pharmacogenomic variants and methotrexate-related neurotoxicity.

Methods: This study included children (aged 2-20 years) diagnosed with ALL (2005-2019) at six treatment centers in the southwest United States.

View Article and Find Full Text PDF

Purpose: In primary central nervous system lymphoma (PCNSL), the extent to which post-methotrexate consolidation contributes to neurotoxicity is unclear. Concerns for neurotoxicity from standard dose whole-brain radiation therapy (WBRT) have led to declining use. Cerebral atrophy is an established surrogate for neurotoxicity; however, the relative extent to which modern consolidation (ie, reduced-dose [RD-]WBRT ≤24 Gy, autologous hematopoietic cell transplant) contributes to cerebral atrophy is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Methotrexate (MTX) is the main treatment for pediatric acute lymphoblastic leukemia (ALL), but some patients experience delayed clearance of high-dose MTX, leading to severe side effects.
  • Whole-exome sequencing was conducted on 51 Korean pediatric ALL patients, analyzing 341 HD-MTX infusion data points to find genetic variants linked to delayed MTX clearance.
  • Two specific genetic variants, rs1800956 and rs16954698, were identified as significantly associated with this delayed clearance, offering potential pathways to reduce toxic side effects through tailored treatments.
View Article and Find Full Text PDF

Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats.

J Psychopharmacol

November 2024

Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ain Shams University, Cairo, Egypt.

Background: Methotrexate (MTX) is a cytotoxic drug that can trigger neurotoxicity via enhancing oxidative stress, apoptosis, and inflammation. On the other hand, erythropoietin (EPO) functions as an antioxidant, anti-apoptotic, and anti-inflammatory agent, in addition to its hematopoietic effects.

Aim: The present study was developed to examine the neuroprotective impact of EPO against MTX-provoked neurotoxicity in rats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!